Below is a summary of the meeting after hearing testimony from Lyme patients seen in the video link of the previous petition update.

Laura Hovid's written testimony:
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/29506824

Carl Tuttle's written testimony:
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/29512492

---------- Original Message ----------

From: CARL TUTTLE runagain@comcast.net
To: Leah Cushman <Leah.Cushman@leg.state.nh.us>, Jerry Knirk Jerry.Knirk@leg.state.nh.us
Cc: All members of the NH Lyme Disease Study Commission
"tickbornedisease@hhs.gov" tickbornedisease@hhs.gov
Date: 08/29/2021 1:50 PM
Subject: Summary of the Aug 23rd meeting of the NH Lyme Disease Study Commission

To the Members of the NH Lyme Disease Study Commission,

Based on what we learned from Laura Hovind, Executive Director of TruthCures, this Lyme travesty is a result of the rush to create a vaccine as the case definition (2 of 3 IgM and 5 of 10 IgG Western blot bands) was conceived around the swollen knee presentation of the disease. (Allen Steere disease) Those people mounted a robust immune response whereas the very sick did not as reported by Dr. Raymond Dattwyler in the 187 page document from the 1994 FDA meeting. (See attachment)
https://www.dropbox.com/s/72mv10im844q5pd/June%201994%20FDA%20Meeting.pdf?dl=0

Food and Drug Administration Center For Biologics Evaluation and Research June 21, 1994

Open Meeting of: The Vaccines and Related Biologics Products Advisory Committee

Page: 49

Raymond Dattwyler:  “...the ones that failed to mount a vigorous immune response tended to do worse.”

Despite knowing this, they went ahead with the case definition anyway because a chronic relapsing  SERONEGATIVE disease did not fit the vaccine model. There would be no way to prove vaccine efficacy otherwise.

To this day the CDC refuses to acknowledge the immunosuppressive nature of the disease.

This is why  stage 3 Lyme is a swollen knee/arthritis  and nothing more as defined by Dr. Isabella Martin and Dr. Ben Chan in previous Zoom meetings.

As a result, serology misses a large number of Lyme patients who are overwhelming the caseloads of the front-line Lyme treating clinicians as these patients have missed the narrow window of opportunity for successful short-term treatment.

I have a copy of Lyme patient Ashley Lynch’s Western blot who testified from her wheelchair last Monday. Her lab test was CDC NEGATIVE but clearly showed exposure to the causative agent of Lyme disease. All Tuttle family members were CDC NEGATIVE.

So the talk on the street is that this TBDWG is just a pacifier to give the impression that or public health officials actually care and have everything under control while the vaccine agenda quietly marches on in the background as the FDA has fast tracked Valneva's human Lyme disease vaccine. [1] These vaccine trials will be validated using current serology designed to detect only the rare arthritis cases while excluding the majority whose illness is driven by immunosuppression. [2] Serology was deliberately manipulated to facilitate vaccine development while the sickest of the patient population  does not  test positive.

This is maleficence left uncheck for 27 years.

Allen Steere (Rheumatologist) was the Principal Investigator of the first human Lyme vaccine (LYMErix) and one of the lead authors of the IDSA Lyme treatment guidelines; a flagrant conflict of interest.

As we heard from patient testimony, faulty/misleading antibody tests [3] are causing great harm to New Hampshire citizens as they are no better than a coin toss. There is no oversight and no one is held accountable.

Everyone reading this email is a single tick bite away from experiencing this travesty (if it hasn’t happened already).

We are experiencing a public health crisis!

Respectfully submitted,

Carl Tuttle
Hudson, NH

Cc: John Formella, Attorney General of New Hampshire
Linden Hu, MD and Holiday Goodreau, Co-chairs of the TBDWG

References

1. VALNEVA Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15
https://www.globenewswire.com/news-release/2017/07/24/1055914/0/en/VALNEVA-Receives-FDA-Fast-Track-Designation-for-its-Lyme-Disease-Vaccine-Candidate-VLA15.html

2. Seronegative Chronic Relapsing Neuroborreliosis.
https://www.ncbi.nlm.nih.gov/pubmed/7796837

3. Sensitivity/specificity of commercial two tier testing for convalescent/late stage Lyme disease in the US
https://www.dropbox.com/s/rgf47nhaqhognw0/Sensitivity-Specificity.jpg?dl=0